Sign In
Last checked at 
27 Feb 2025 07:00
IXICO PLC
("IXICO" or the "Company")
Contract Wins in Alzheimer's and Huntington's Disease
27 February 2025 - London, UK. IXICO plc (AIM: IXI, "IXICO" or "the Company") a global leader in neuroscience imaging, using its AI-driven platform to help advance therapy research in neurological disorders, today announces that it has signed a new commercial contract for a global Alzheimer's Disease (AD) imaging analysis with a leading biotechnology company, and secured an additional project in Huntington's Disease (HD) with an existing partner.
The combined value of the new contracts is more than £0.5 million, which will be recognised within a year, and increases the proportion of expected revenues for FY25 now contracted.
The positive commercial momentum continues IXICO's successful execution of its 'Innovate, Lead, Scale' strategy to drive expansion and growth. The nature of both agreements provides the potential for further revenues in the future.
New AD Contract
The AD contract is with a multinational biotechnology company, to provide imaging reads and data analysis using the dataset from the Global Alzheimer's Platform Foundation's groundbreaking Bio-Hermes-001 study, of which IXICO is a partner.
Additional HD Contract
The US headquartered client that contracted the Company to conduct a Phase 2 HD clinical trial, as announced on 10 December 2024, has subsequently deepened and extended its commercial partnership. Underlining IXICO's leading HD imaging platform status, a new project is being undertaken using the 'IXIQ.Ai' platform to reanalyse data from a previous Phase I clinical trial.
Bram Goorden, CEO of IXICO, commented: "The AD trial is a significant win for IXICO in that it complements the Company's strategy of expanding neuroimaging biomarker analysis for partners into the clinical diagnostics market. Both the AD contract win, and new HD project, reflect the continued recognition of IXICO as a global neuroimaging market leader with an unrivalled biomarker technology advantage."
Ends
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the UK version of the EU Market Abuse Regulation 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018, as amended and supplemented from time to time. Upon the publication of this announcement, this inside information is now considered to be in the public domain.
Further information:
IXICO plc | +44 (0) 20 3763 7499 |
Bram Goorden, Chief Executive Officer Grant Nash, Chief Financial Officer | |
Cavendish Capital Markets Limited (Nominated Adviser and Sole Broker) | +44 (0) 20 7220 0500 |
Giles Balleny / Dan Hodkinson (Corporate Finance) Nigel Birks/Harriet Ward (Corporate Broking) Michael F Johnson / Tamar Cranford Smith (Sales) |
About IXICO www.IXICO.com
IXICO is dedicated to delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's disease, Parkinson's disease and Alzheimer's disease. The Company's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience by supporting pharmaceutical companies across all phases of CNS clinical research. IXICO's goal is to be a leading advocate of artificial intelligence in medical image analysis.
IXICO has developed and deployed breakthrough data analytics, at scale, through its remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for the Company's pharmaceutical clients.
Follow the stocks
